Abstract
We examined the effects of Herceptin, a bioengineered monoclonal antibody directed against Her-2/neu oncogene on skeletal metastasis using a xenograft model of breast cancer. Treatment of Her-2 overexpressing human breast cancer cells BT-474 with Herceptin caused a dose-dependent decrease in cell proliferation. In in vivo studies, BT-474 cells (1 × 105) were injected into the left ventricle of female BALB/c nu/nu mice. Intraperitoneal (i.p.) infusion of Herceptin (1 mg/kg twice a week for 5 weeks) from the day of tumor cell inoculation or at the time of radiologically detectable skeletal metastasis either slowed the development or prevented the progression of skeletal metastasis as compared to control groups of animals receiving nonspecific IgG. Bone histological analysis of long bones showed the ability of Herceptin to reduce the ratio of tumor volume to bone volume as well as mitotic index, effects that were more pronounced when Herceptin treatment was initiated from the day of tumor cell inoculation. While immunohistochemical analysis of long bones showed no difference in the production of Her-2, phosphorylated (P) Her-2 and MAPK, a significantly lower level of P-MAPK was seen in bones of Herceptin treated animals. These studies demonstrate the ability of Herceptin to inhibit the development and abrogate the progression of skeletal metastases associated with breast cancer by blocking the HER-2-mediated signaling pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adewale A, Nui Y, Cherlet T, Snell L, Watson PH and Murphy LC . (2002). Clin. Cancer Res., 8, 1747–1753.
Baselga J, Norton L, Albanell J, Kim Y-M and Mendelsohn J . (1998). Cancer Res., 58, 2825–2831.
Bell R . (2002). Oncology, 63 (Suppl 1), 39–46.
Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW and Suva LJ . (2002). Cancer Res., 62, 5571–5579.
Bernstein L . (2002). J. Mammary Gland Biol. Neoplasia, 7, 3–15.
Cheng JD, Rieger PT, von Mehren M, Adams GP and Weiner LM . (2000). Semin. Oncol. Nurs., 16 (Supp1), 2–12.
DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD and Stern DF . (1998). Oncogene, 17, 1877–1884.
Duivenvoorden WC, Popovic SV, Lhotak S, Seidlitz E, Hirte HW, Tozer RG and Singh G . (2002). Cancer Res., 62, 1588–1591.
El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG and Kremer R . (2000). Cancer Res., 60, 4412–4418.
Esteva FJ, Valero V, Pusztai L, Beohnke-Michaud L, Buzdar AU and Hortobagyi GN . (2001). Oncologist, 6, 133–146.
Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL and Foekens JA . (1994). Breast Cancer Res. Treat., 29, 73–83.
Kurebayashi J . (2001). Breast Cancer, 8, 45–51.
Lacroix M and Leclercq G . (2004). Breast Cancer Res. Treat., 83, 249–289.
Margolese TG, Hortobagy GN and Buchholz TA . (2003). Cancer Medicine 6th edn BC Decker Inc.: Canada, pp. 1879–1970.
Masood S and Bui MM . (2002). Microsc. Res. Tech., 59, 102–108.
Mayfield S, Vaughn JP and Kute TE . (2001). Breast Cancer Res. Treat., 70, 123–129.
Moasser MM, Basso A, Averbuch SD and Rosen N . (2001). Cancer Res., 61, 7184–7188.
Mundy GR . (2002). Nat. Rev. Cancer, 2, 584–593.
Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, ciardiello F, Gianni L, Salomon DS and Menard S . (2002). Ann. Oncol., 13, 65–72.
Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D and Benz CC . (2002). Clin. Cancer Res., 8, 1172–1181.
Pluijm G, Lowik C and Papapoulos S . (2000). Cancer Treat. Rev., 26, 11–27.
Rabbani SA, Khalili P, Arakelian A, Pizzi H, Chen G and Goltzman D . (2005). Endocrinology, 146, 2885–2894.
Roodman D . (2003). Cancer, 97 (Supp l), 733–738.
Ross JS and Fletcher JA . (1998). Stem Cells, 16, 413–428.
Shafie SM and Grantham FH . (1981). J. Natl. Cancer Inst., 67, 51–56.
Sliwowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA . (1999). Semin. Oncol., 26, 60–70.
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL . (2002). Cancer Res., 62, 4132–4141.
Yarden Y . (2001). Oncology, 61 (Suppl 2), 1–13.
Zhou BP and Hung MC . (2003). Semin. Oncol., 30 (Suppl 16), 38–48.
Acknowledgements
We thank Dr Ida Khalili, Department of Radiology, McGill University Health Centre for carefully reviewing all X-rays. This work was supported by the Canadian Institutes of Health Research (CIHR) Grant MOP 10630 to SA Rabbani.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khalili, P., Arakelian, A., Chen, G. et al. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene 24, 6657–6666 (2005). https://doi.org/10.1038/sj.onc.1208790
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208790
Keywords
This article is cited by
-
Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET
European Journal of Nuclear Medicine and Molecular Imaging (2021)
-
Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns
Journal of Molecular Medicine (2015)
-
A Methodological Approach to Unravel Organ-Specific Breast Cancer Metastasis
Journal of Mammary Gland Biology and Neoplasia (2012)
-
Epidermal growth factor signalling and bone metastasis
British Journal of Cancer (2010)
-
Metastasis: a therapeutic target for cancer
Nature Clinical Practice Oncology (2008)